Characteristics | Total |
---|---|
Age | 50(43–55) |
Current smoking, N (%) | 1(1) |
Hormone receptor status, N (%) | |
ER+ | 89(60) |
ER + PR+ | 83(56) |
ER + PR- | 5(3) |
ER-PR- | 35(23) |
HER2+ | 12(8) |
ER-PR-HER2- | 18(12) |
Family history of breast cancer, N (%) | 25(17) |
Post-menopausal, N (%) | 111(76) |
Hormone therapy for breast cancer | 112(76) |
Stage, N (%) | |
Stage I | 33(22) |
Stage II | 61(41) |
Stage III | 35(24) |
Missing | 18(13) |
Recurrence N (%) | |
Yes | 5(3) |
No | 77(67) |
Unknown | 65(30) |
Physical activity levels, N (%) | |
Low physical activity | 80(54) |
Moderate physical activity | 44(30) |
High physical activity | 23(16) |
Energy intake, Kcal | 1901(1832–2046) |
Fat intake, grams | 84 ± 16 |
Protein intake, grams | 56(49–62) |
Carbohydrate intake, grams | 243 ± 41 |
Pre intervention Vitamin D, nmol/liter | 38(22–62) |
Post intervention vitamin D, nmol/liter | 110 ± 46 |
ApaI N (%) | |
AA | 68(49) |
Aa | 52(38) |
aa | 18(13) |
TaqI N (%) | |
TT | 57(41) |
Tt | 67(49) |
tt | 14(10) |
BsmI N (%) | |
BB | 66(45) |
Bb | 65(44) |
bb | 16(11) |
FokI N (%) | |
FF | 64(44) |
Ff | 66(45) |
ff | 17(12) |
Cdx2 N (%) | |
GG | 81(55) |
AG | 52(35) |
AA | 14(10) |